Lupin acquires diabetes trademarks from Boehringer Ingelheim to bolster treatment portfolio

Pallavi Madhiraju- December 14, 2024 0

Lupin Limited, a global pharmaceutical leader based in Mumbai, has announced the acquisition of three anti-diabetes trademarks—GIBTULIO, GIBTULIO MET, and AJADUO—from Boehringer Ingelheim International GmbH. ... Read More

Lilly commits $3bn to Wisconsin facility to boost injectable medicine production

Pallavi Madhiraju- December 6, 2024 0

Eli Lilly and Company (Lilly) has unveiled plans for a $3 billion expansion of its newly acquired manufacturing facility in Kenosha County, Wisconsin, signalling a ... Read More

Eli Lilly’s stock plummets over missed sales forecasts for Mounjaro, Zepbound – what’s next for the pharma giant?

Pallavi Madhiraju- October 30, 2024 0

Eli Lilly & Co. has faced a dramatic drop in its stock price, tumbling over 10% following a critical earnings report that highlighted missed revenue ... Read More

vTv Therapeutics and OnKure part ways, dissolving pivotal cellular drug agreement

Pallavi Madhiraju- October 26, 2024 0

vTv Therapeutics, a clinical-stage biopharmaceutical company known for its innovative approach in diabetes treatment, and OnKure Therapeutics, an oncology-focused pharmaceutical company, have announced the termination ... Read More

Eli Lilly to expand manufacturing with $1bn investment in Ireland to boost Alzheimer’s drug production

Pallavi Madhiraju- September 14, 2024 0

Eli Lilly and Company (NYSE: LLY) has announced a substantial $1 billion investment to expand its Limerick, Ireland, manufacturing site, which will increase the production ... Read More

TUXEDO-2 trial wraps up enrolment: Could Sahajanand Medical Technologies’ stent revolutionise diabetes care?

Pallavi Madhiraju- August 18, 2024 0

In a landmark achievement for cardiovascular medicine, Sahajanand Medical Technologies has announced the successful completion of patient enrolment for the TUXEDO-2 clinical trial in India. ... Read More

Setback for diabetes innovation: FDA puts brakes on Novo Nordisk’s once-weekly insulin icodec

Pallavi Madhiraju- July 11, 2024 0

Novo Nordisk announced that the US Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) regarding the Biologics License Application for its ... Read More

Unveiling the Therapeutic Power of Agnimantha: A Holistic Approach to Wellness

Pallavi Madhiraju- March 10, 2024 0

Agnimantha, scientifically recognized as Premna integrifolia L., is a traditional medicinal herb that plays a crucial role in Ayurvedic medicine. Known by various names such ... Read More

Novo Nordisk’s Fiasp gains FDA approval for fast-acting insulin, enhancing diabetes management in US

pharmanewsdaily- October 2, 2017 0

Novo Nordisk, a leading Danish pharmaceutical company, has secured a significant regulatory milestone with the US FDA approval of its innovative fast-acting mealtime insulin aspart ... Read More

FDA approves Novo Nordisk’s Victoza for heart disease treatment in type 2 diabetes patients

pharmanewsdaily- August 26, 2017 0

In a significant advancement for diabetes care, Danish pharmaceutical giant Novo Nordisk has received approval from the U.S. Food and Drug Administration (FDA) to use ... Read More